Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OpsiProst
- Development stage
- Preclinical
- Lead developer
- Biodexa Pharmaceuticals
- Administration
- Ophthalmic
01
Overview
OpsiProst is an investigational ocular drug delivery product being developed by OpsiRx Pharmaceuticals that is designed to provide a long-duration formulation of a prost-based (likely prostaglandin-analog) therapy for ophthalmic use, such as in glaucoma or other chronic eye conditions requiring sustained intraocular pressure control.[9][14] It is part of OpsiRx’s portfolio of extended-release ocular products that use proprietary drug delivery technology to achieve prolonged therapeutic levels in the eye, with the goal of reducing dosing frequency and improving patient adherence compared with conventional eye-drop formulations.[9] Detailed molecular composition, specific active ingredient, and precise mechanism of action have not yet been publicly disclosed.
- Brand names
- OpsiProst
Beyond the preview
Go deeper on OpsiProst.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OpsiProst.